SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 784.45-0.4%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (1747)4/30/2015 12:29:37 PM
From: Miljenko Zuanic  Read Replies (1) of 3559
 
Eylea (ROW) sales for 1Q v 4Q (per Bayer) are E253 v 219, or 15% increase. IF this hold for US it will be hyped in 1Q PR, but expense will skyrocket due to R&D/COGS, marketing, and capital expenditures (Ireland plant). Stock price may suffer from high-expectation, but progress on many programs leave me with confidence that future is still very positive.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News